New antibody injection aims to tame stubborn sinusitis

NCT ID NCT06439381

Completed Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests a drug called TQH2722, a lab-made antibody that blocks inflammation, for people with severe chronic sinusitis (with or without nasal polyps). About 120 adults who completed a prior TQH2722 study will receive either 300mg or 600mg injections over a long period. Researchers will track side effects and how well the drug controls sinus symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQH2722 injection (a lab-made antibody that blocks inflammation signals)
What this could lead to: If it works, this could provide a new long-term treatment option for people with severe chronic sinusitis, reducing symptoms and the need for surgery.
What could go wrong: This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drug could cause side effects or fail to show clear benefit over existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic rhinosinusitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS

Contacts and locations

Locations

Baotou Central Hospital

Baotou, Inner Mongolia, 014000, China
Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, 100730, China
Cangzhou Central Hospital

Cangzhou, Heibei, 061017, China
Chengdu Second People's Hospital

Chengdu, Sichuan, 610021, China
First Hospital of Shangxi Medical University

Taiyuan, Shangxi, 030001, China
Guangxi Medical University Cancer Hospital

Nanning, Guangxi, 530021, China
Hebei Medical University Third Hospital

Shijiazhuang, Hebei, 050000, China
Henan Provincial People's Hospital

Zhengzhou, Henan, 450003, China
Jilin Provincial People's Hospital

Changchun, Jilin, 130021, China
Loudi Central Hospital

Changsha, Hunan, 417000, China
Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008, China
Renji Hospital Shanghai Jiaotong University School of Medical

Shanghai, Shanghai Municipality, 200127, China
Renmin Hospital of Wuhan University Hubei General Hospital

Wuhan, Hubei, 430060, China
Shandong Second People's Hospital

Jinan, Shandong, 250299, China
Shengjing Hospital Affiliated to China Medical University

Shenyang, Liaoning, 110004, China
Taizhou central hospital(Taizhou university hospital)

Taizhou, Zhejiang, 318000, China
The Affiliated Hospital of Yanbian University

Yanji, Jilin, 133002, China
The Central Hospital of Shenyang Medical College

Shenyang, Liaoning, 110075, China
The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830011, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110002, China
The First People's Hospital of Foshan

Foshan, Guangdong, 528000, China
The Second People's Hospital of Shenzhen

Shenzhen, Guangdong, 518035, China
Union Hospital, Tongji Medical College, Huazhong University of science and technology

Wuhan, Hubei, 430022, China
Weihai Central Hospital

Weihai, Shandong, 264499, China
Wenling First People's Hospital

Wenling, Zhejiang, 317599, China
Yantai Yuhuangding Hospital

Yantai, Shandong, 264000, China
Zibo Central Hospital

Zibo, Shandong, 255036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.